Monoclonal Antibody Therapeutics Market set to rise $558.1 billion by 2030, as Increasing emphasis on immuno-oncology hits transformation ground

Datastring Consulting

posted on 1 day ago — updated on 1 second ago

15
views

According to a recent research, Industry revenue for Monoclonal Antibody Therapeutics is expected to rise to $558.1 billion by 2030 from $228.6 billion of 2023. The revenue growth of industry players is estimated to average at 13.6% annually for period 2023 to 2030. Growing end-industry applications in major countries like U.S., Germany and Japan, is driving the market demand high.

Research Study analyse the new revenue pockets, emerging markets, competition landscape, opportunities & niche insights for Therapy (Oncology, Autoimmune Diseases, Infectious Diseases, Others), Application (Cancer, Rheumatoid Arthritis, Inflammatory Diseases, Others) and End-User (Hospitals, Specialty Clinics, Research Institutes, Others).

Access the detailed report here - https://datastringconsulting.com/industry-analysis/monoclonal-antibody-therapeutics-market-research-report

Regional Analysis

North America and Asia-Pacific are the two most active and leading regions in the market. Major companies, in the Asia Pacific region like Taked and Samsung Biologics are experiencing growth due to collaborations and the expanding biosimilars market. This growth is particularly notable in nations such, as South Korea and Japan.The Asia Pacific region experiences advantages from cost-efficient manufacturing and the rising demand, within the region. This is particularly evident in emerging markets such as India and China where there is an increase, in healthcare infrastructure development.

With challenges like high production costs and stringent regulatory approvals, Monoclonal Antibody Therapeutics market’s supply chain from raw material suppliers to distributors and healthcare providers is expected to evolve & expand further; and industry players will make strategic advancement in emerging markets including India, Brazil and South Korea for revenue diversification and TAM expansion. In the field of cancer research today immunotherapy and monoclonal antibodies are leading the charge in enhancing the bodys defenses, against cancer cells.

Industry Leadership and Strategies

The Monoclonal Antibody Therapeutics market is characterized by intense competition, with a number of leading players such as Roche, Amgen, AbbVie, Bristol-Myers Squibb, Janssen, Pfizer, Eli Lilly, Novartis, GSK, Merck, AstraZeneca and Sanofi.

About DataString Consulting

DataString Consulting assist companies in strategy formulations & roadmap creation including TAM expansion, revenue diversification strategies and venturing into new markets; by offering in depth insights into developing trends and competitor landscapes as well as customer demographics. Our customized & direct strategies, filters industry noises into new opportunities; and reduces the effective connect time between products and its market niche.

DataString Consulting offers complete range of market research and business intelligence solutions for both B2C and B2B markets all under one roof. DataString’s leadership team has more than 30 years of combined experience in Market & business research and strategy advisory across the world. Our Industry experts and data aggregators continuously track & monitor high growth segments within more than 15 industries and 60 sub-industries.